Martínez Rodríguez, Antón LeandroBrea Floriani, José ManuelLópez, D.Cosme Boullosa, NeilaBarro Fernández, MateoMonroy, X.Burgueño, J.Merlos, M.Loza García, María Isabel2024-05-202024-05-202024Pharmacological Research, Volume 202, 2024, 1071111043-6618http://hdl.handle.net/10347/33869The discovery of brain therapeutics faces a significant challenge due to the low translatability of preclinical results into clinical success. To address this gap, several efforts have been made to obtain more translatable neuronal models for phenotypic screening. These models allow the selection of active compounds without predetermined knowledge of drug targets. In this review, we present an overview of various existing models within the field, examining their strengths and limitations, particularly in the context of neuropathic pain research. We illustrate the usefulness of these models through a comparative review in three crucial areas: i) the development of novel phenotypic screening strategies specifically for neuropathic pain, ii) the validation of the models for both primary and secondary screening assays, and iii) the use of the models in target deconvolution processesengAtribución 4.0 Internacional© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)http://creativecommons.org/licenses/by/4.0/Phenotypic screeningImmortalized cell linesIn vitro modelsNeuropathic painIn vitro pharmacologyEarly drug discoveryjournal article10.1016/j.phrs.2024.107111open access